文献速递认知障碍与痴呆

预防阿尔茨海默病所致认知障碍的路径:美国启动的倡议

A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA.
PubMed 文献 · Lancet Neurol · 2026-01-01

抗体疗法可清除大脑淀粉样斑块并减缓轻度受损阿尔茨海默病患者的认知下降。这些药物正在认知未受损但阿尔茨海默病生物标志物阳性的参与者中评估安全性、耐受性、疾病修饰和认知保护效果及预防认知障碍发作的能力。本文评估这些药物试验带来的挑战与机遇,并考虑 enabling 批准、可负担性、医保覆盖和公平使用所需的血液检测、认知评估和上市后策略。

要点

  • 抗体疗法在轻度受损阿尔茨海默病患者中可清除淀粉样斑块并减缓认知下降。
  • 正在认知未受损但生物标志物阳性者中评估安全性、耐受性及预防认知障碍的效果。
  • 需血液检测、认知评估和上市后策略以支持批准、可负担性、医保覆盖和公平使用。

核心结论

  • 若在认知未受损但生物标志物阳性者中的试验成功且药物获批,可加速相关疾病修饰治疗的评估和批准。

研究设计与样本

  • 本文为政策观点文章,评估抗体疗法试验的挑战与机遇,并提出建议供美国考虑。

主要发现

  • 抗体疗法可清除大脑淀粉样斑块并减缓轻度受损阿尔茨海默病患者的认知下降。
  • 这些药物正在认知未受损但阿尔茨海默病生物标志物阳性的参与者中评估安全性、耐受性、疾病修饰和认知保护效果及预防认知障碍发作的能力。
  • 临床前阿尔茨海默病治疗和一级预防治疗有可能显著预防阿尔茨海默病的后续生物学和临床表现。

临床怎么用

  • 建议涉及血液检测、认知评估和上市后策略,以支持批准、可负担性、医保覆盖和公平使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibody therapies can remove amyloid plaques from the brain and slow cognitive decline in people with Alzheimer's disease who are mildly impaired. These drugs are now being evaluated in participants who are cognitively unimpaired but positive for a biomarker of Alzheimer's disease for their safety, tolerability, disease-modifying and cognitive preserving effects, and ability to avert the onset of cognitive impairment. If these studies are successful, and the drugs get regulatory approval, they could accelerate the evaluation and approval of related Alzheimer's disease-modifying treatments in people who are unimpaired with or without a biomarker of the disease. Preclinical Alzheimer's disease therapies that modify the underlying disease in people who are unimpaired with a biomarker of Alzheimer's disease and primary prevention therapies that avert the onset of amyloid plaques in those with a negative test have the potential to substantially prevent ensuing biological and clinical manifestations of Alzheimer's disease. In this Policy View, we assess the challenges and opportunities that trials of these drug treatments will bring, and consider the blood tests, cognitive assessments, and post-marketing strategies needed to enable the approval, affordability, health-care insurance coverage, and equitable use. Our recommendations are intended for consideration in the USA, and relevant refinement in other countries.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Reiman EM, Alexander RC, Langbaum JB, et al. A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA. Lancet Neurol. 2026. PMID: 41722593. doi:10.1016/S1474-4422(25)00483-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。